Compare Inovio Pharmaceuticals Inc (INO) vs BlackRock TCP Capital Corp (TCPC) Price & Performance

INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.

The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.

TCPC trades at $4.01, up 1.78% with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $0.22, beating expectations, and announced a $523 million portfolio sale to reduce leverage. Despite negative revenue and net income trends, the stock trades at a discount to book value with a P/B of 0.61. Analyst consensus shows 30.77% buy ratings with no sell recommendations.

The outlook remains cautious due to declining revenue and negative profitability metrics, though strategic portfolio sales and dividend payments provide some stability. Key risks include ongoing net losses and class action litigation, while institutional sentiment appears mixed with technical indicators suggesting near-term bullish momentum.